Histogenics Acquires Rights to NeoCart for the Japanese Market

Histogenics acquired development and commercialization rights to NeoCart® for the Japanese market from its development partner Purpose Co. NeoCart autologous cell therapy is designed to treat knee cartilage defects.

Histogenics notes that the Japanese market for cartilage repair is estimated at >200,000 procedures...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us